tildrakizumab (Ilumetri) Report issue

Biologics mAb Approved FDA
AACT ChEMBL Drugs@FDA MeSH

Active Ingredient History

NOW
  • Now
Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$2453.1965

United States

$9184.3700
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

mk-3222 | sch 900222 | tildrakizumab | tildrakizumab-asmn

Organizations (19)

Research & Development (19)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

Psoriasis (approved 2018)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Aging (Phase 4)

Arthritis, Psoriatic (Phase 3)

Biological Products (Early Phase 1)

Genetic Diseases, Inborn (Phase 4)

Hematologic Neoplasms (Phase 2)

Hypopigmentation (Early Phase 1)

Inflammation (Phase 4)

Pemphigoid, Bullous (Early Phase 1)

Pigmentation Disorders (Early Phase 1)

Prostatic Neoplasms, Castration-Resistant (Phase 1/Phase 2)

Psoriasis (Phase 4)

Skin and Connective Tissue Diseases (Early Phase 1)

Skin Diseases (Early Phase 1)

Spondylitis, Ankylosing (Phase 2)

Vitiligo (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 28
  • # of Trial Organizations: 19

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue